Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Trump Says Anthropic No Longer Seen as National Security Threat 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
VALENCIA, Calif., Jan. 27, 2016 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Medical Officer, Raymond Urbanski.
To view and listen to the webcast, visit MannKind’s website at http://www.mannkindcorp.com and click on the “MannKind 2/3/16 Conference Call” link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 41729996. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4172 9996#. A replay will also be available on MannKind's website for 14 days.
As with past calls, the Company will take live questions from covering analysts. However, departing slightly from past practice for this call, stockholders who wish to submit questions in advance of the call should email them to [email protected].
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact:
Matthew J. Pfeffer
Chief Executive Officer
661-775-5300
[email protected]
